Performance characteristics of the first Food and Drug Administration (FDA)-cleared digital droplet PCR (ddPCR) assay for BCR::ABL1 monitoring in chronic myelogenous leukemia

Assessment of droplet digital polymerase chain reaction for measuring BCR‐ABL1 in chronic myeloid leukaemia in an international interlaboratory study

(2021) Stuart Scott et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prospects for achieving treatment‐free remission in chronic myeloid leukaemia

(2020) Giuseppe Saglio et al.   BRITISH JOURNAL OF HAEMATOLOGY

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

(2020) A. Hochhaus et al.   LEUKEMIA

Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

(2020) Michael W. Deininger et al.   Journal of the National Comprehensive Cancer Network

Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?

(2020) Gioia Colafigli et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia

(2020) Ehab Atallah et al.   JAMA Oncology

The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview

(2019) Michele Baccarani et al.   LEUKEMIA

Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA

(2019) Justin T. Brown et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation

(2019) Simona Bernardi et al.   Cancer Medicine

Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping Imatinib first-line in chronic phase CML Patients

(2019) Franck Emmanuel Nicolini et al.   CLINICAL CANCER RESEARCH

Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia

(2019) Matteo Dragani et al.   LEUKEMIA & LYMPHOMA

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

(2019) Andrea Forschner et al.   Journal for ImmunoTherapy of Cancer

Comparison of Real-Time Quantitative PCR and Digital Droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia

(2019) Georg-Nikolaus Franke et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients

(2018) Marius Bill et al.   ANNALS OF HEMATOLOGY

Quantification of Residual BHK DNA by a Novel Digital Droplet PCR Technology

(2018) Yu Wang et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

(2018) Susanne Saussele et al.   LANCET ONCOLOGY

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

(2018) Jerald P. Radich et al.   Journal of the National Comprehensive Cancer Network

Optimized Digital Droplet PCR for BCR-ABL

(2018) Jacqueline Maier et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

(2017) Gabriel Etienne et al.   JOURNAL OF CLINICAL ONCOLOGY

Droplet Digital PCR Is a Reliable Tool for Monitoring Minimal Residual Disease in Acute Promyelocytic Leukemia

(2017) Claudia Brunetti et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation

(2016) Matthew P. Mulé et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Moving treatment-free remission into mainstream clinical practice in CML

(2016) Timothy P. Hughes et al.   BLOOD

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

(2016) Geoffrey R. Oxnard et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantification of the Mutant CALR Allelic Burden by Digital PCR

(2016) Olivier Mansier et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale

(2016) N C P Cross et al.   LEUKEMIA

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

(2015) N C P Cross et al.   LEUKEMIA

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

(2015) Isaac Garcia-Murillas et al.   Science Translational Medicine

Considerations for Digital PCR as an Accurate Molecular Diagnostic Tool

(2014) J. F. Huggett et al.   CLINICAL CHEMISTRY

Detection and Quantification of BCR-ABL1 Fusion Transcripts by Droplet Digital PCR

(2014) Lawrence J. Jennings et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Incidence of bcr-abl fusion transcripts in healthy individuals

(2014) SAID I. ISMAIL et al.   Molecular Medicine Reports

BCR–ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring

(2013) Martin H Luu et al.   EXPERT REVIEW OF MOLECULAR DIAGNOSTICS

Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay

(2011) Hyun-Gyung Goh et al.   LEUKEMIA & LYMPHOMA

Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA

(2010) H. E. White et al.   BLOOD

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance

(2009) D. Verma et al.   BLOOD

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

(2008) S. Branford et al.   BLOOD